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Abstract
Goals of work The goal of this study was to examine the
relationship between menopausal symptoms, sleep quality,
and mood as measured by actigraphy and self-report prior
to treatment and at the end of four cycles of chemotherapy
in women with breast cancer.
Patients and methods Data on sleep quality (measured using
actigraphy and self-report) and mood were collected prior to
treatment and 12 weeks later at the end of four cycles of
chemotherapy in 69 women with newly diagnosed breast
cancer. In addition, each filled out the Greene Climacteric
Scale. Based on reported occurrence of menses, participants
were categorized post hoc into three menopausal status
groups: pre-menopausal before and after chemotherapy
(Pre–Pre), pre-menopausal or peri-menopausal before and
peri-menopausal after chemotherapy (Pre/Peri–Peri), and
post-menopausal before and after chemotherapy (Post–Post).
Main results Results suggested that women within the Pre–
Pre group evidenced more fragmented sleep with less total
sleep time (TST) after chemotherapy compared to baseline.
Compared to the other groups, the Pre–Pre group also
experienced less TST and more awakenings before and
after chemotherapy. Although the Pre/Peri–Peri group
evidenced a greater increase in vasomotor symptoms after
chemotherapy, there was no relationship with sleep. All
groups evidenced more depressive symptoms after chemo-
therapy, but depression was not related to measures of
sleep.
Conclusions Contrary to the study hypothesis, these results
suggest that women who are pre-menopausal or having
regular menses before and after four cycles of chemother-
apy have worse sleep following chemotherapy. Those
women who maintain or become peri-menopausal (irregular
menses) experience an increase in climacteric symptoms
but do not experience an associated worsening of sleep.
These results are preliminary and more research is
necessary to further explain these findings.
Keywords Chemotherapy .Menopause . Actigraphy .
Sleep quality . Breast cancer
Introduction
Complaints of insomnia and poor sleep are common in
women going through natural menopause [1]. It is
believed that the primary predictor of disturbed sleep in
peri-menopausal women is the presence of vasomotor
symptoms, i.e., hot flashes [2–4].
Insomnia and poor sleep are two of the most common
symptoms reported by women with breast cancer, with
over 50% of patients complaining of difficulty sleeping
before, during, and after chemotherapy [5]. One signifi-
cant sequelae of chemotherapy is acute ovarian failure
which results in either permanent or temporary amenor-
rhea as well as a sudden onset of the symptoms of
menopause [6–9].
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Earlier detection of breast cancer has lead to an
increasingly young population of women being treated
with chemotherapy, and thus younger women are going
through peri-menopause, i.e., experiencing symptoms of
menopause, including symptoms of insomnia. Hot flashes
in women with breast cancer are associated with poorer
subjective sleep quality [10, 11] and thought to contribute
to poorer, less consolidated sleep by increasing awakenings
and sleep stage changes [3]. Yet, little is known about
whether the poor sleep in women undergoing chemotherapy
is a result of the concurrent menopausal symptoms.
As part of a larger study on the relationship between
sleep and fatigue in women with breast cancer, the current
study examined the effects of menopausal symptoms on
sleep quality during chemotherapy. Participants were
divided post hoc into three menopausal groups based on
their self-reported occurrence of menses before and after
chemotherapy. For the purposes of this study, sleep quality
was defined as the maintenance or change of nighttime
sleep characteristics from before and after chemotherapy
using both objective and subjective measures. The hypoth-
esis was that women experiencing peri-menopause (defined
as irregular menses) at either point during chemotherapy
would have worse sleep quality at the end of treatment than
pre- or post-menopausal women.
Methods
Patients
Sixty-nine women diagnosed with stage I–III breast
cancer and referred for at least four cycles of adjuvant
(chemotherapy after surgery) or neo-adjuvant (chemother-
apy before surgery) anthracycline-based chemotherapy
were studied (see Fig. 1). Potential participants were
recruited from the Rebecca and John Moores University of
California—San Diego (UCSD) Cancer Center. Exclusion
criteria included women undergoing bone marrow trans-
plants, metastatic breast cancer, confounding underlying
medical illnesses such as renal failure or significant pre-
existing anemia, or other physical or psychological
impairments which would limit participation. The study
was approved by both the UCSD Human Research
Protection Program and the San Diego State University
Human Research Protection Program.
Study design
Most data were collected at seven time points: prior to
chemotherapy, during the three weeks of cycle 1, and
during the three weeks of cycle 4 chemotherapy. Meno-
pausal symptoms and status were collected only prior to
chemotherapy and during the recovery or third week of
cycle 4 of chemotherapy (end of fourth cycle of treatment).
Therefore, only data collected at those two time points were
analyzed. Each chemotherapy cycle was three weeks in
duration; therefore, the interval from baseline to the end of
treatment was 12 weeks. At the start of the study, body
weight and height were measured as were general demo-
graphics. Body mass index was calculated (in kg/m2).
Women were divided post hoc into three groups based
on self-report of the occurrence of menses both prior to
chemotherapy and during the recovery week of cycle 4
chemotherapy: group 1, called Pre–Pre (N=12), was
composed of women who reported regular menstrual cycles
both before and after chemotherapy, group 2, called Pre/
Peri–Peri (N=21), was composed of women who reported
irregular menses after chemotherapy but had reported either
regular or irregular menses before chemotherapy (combined
due to small group size), and group 3, called Post–Post
(N=36), was composed of women with amenorrhea before
Assessed for eligibility (n=132)
Excluded (n=37)
Not meeting inclusion criteria
(n=18)
Refused to participate 
(n=19)
Completed (n=89)
Enrollment (n=95) 
Dropped after enrollment (n=6) 
Non-compliant 
(n=1) 
Study become overwhelming 
(n=5) 
Participants in this study (n=69) 
Dropped from analysis (n=20) 
Menopausal status could not be  
determined (n=16) 
Baseline actigraphy data  
unavailable (n=11) 
CES-D total score unavailable for 
pre and post treatment (n=1) 
Enrollment 
Analysis 
Completed 
Eligibility 
Fig. 1 Screening and enrollment flowchart
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and after chemotherapy, including women that were post-
hysterectomy and/or post-oophorectomy.
Sleep measurements
(a) Wrist actigraph. The Actillume II actigraph (Ambula-
tory Monitoring, Inc., Ardsley, NY, USA) was worn
by each patient for 72 consecutive hours (3 days and
3 nights) at all seven time points. The Actillume II
contains a piezoelectric linear accelerometer, a micro-
processor, 32 K-byte random access memory, and
associated circuitry for the purpose of recording
intensity and frequency of movement. The orientation
and sensitivity of the accelerometer are optimized for
highly effective sleep–wake inference from wrist
activity [12–14]. Actigraphic records were scored with
Action 3 (Ambulatory Monitoring, Inc., Ardsley, NY,
USA) for total sleep time (TST) at night, wake after
sleep onset (WASO), and sleep percentage (%). Sleep
onset latency, or time to fall asleep, has been found to
be inaccurate when using actigraphy and is therefore
not included as a parameter. Sleep percentage is
defined as the percent time asleep after sleep onset
and does not include the less reliable parameter of
sleep onset latency [15]. The number (NWAK) and
mean duration of nighttime awakenings and sleep
bouts were extracted from the scored actigraphic
records using SAS® software, version 9.1.3 [16]. A
daily sleep diary was used to validate time in bed and
time awake.
(b) Pittsburgh Sleep Quality Index [PSQI; 17]. The PSQI
is a 19-item questionnaire which rates patients’ reports
of their sleep quality based on ratings of subjective
sleep latency, sleep duration, habitual sleep efficiency,
sleep disturbances, use of sleep medication, and
daytime dysfunction. The global score may range
from 0 to 21 with high scores reflecting poor sleep
quality. A global score above 5 is generally considered
poor sleep.
Other measurements
(a) Climacteric status. Climacteric status was reported
using one of four descriptors: (1) regular menses
before/after chemotherapy, (2) irregular menses before/
after chemotherapy, (3) post-menopausal before/after
chemotherapy, and (4) post-hysterectomy/oophorecto-
my before/after chemotherapy.
(b) Greene Climacteric Scale [18]. Climacteric symptom-
atology was assessed with the Greene Climacteric
Scale, a self-report questionnaire that measures a total
of 21 physical and psychological symptoms associated
with the menopause transition. Each symptom is rated
by the respondent according to its severity using a
four-point scale: not at all (0), a little (1), quite a bit
(2), and extremely (3). Items 1–11 address anxiety
(items 1–6) and depression (items 7–11); examples
include ‘difficulty in sleeping’ and ‘feeling unhappy or
depressed.’ The anxiety and depression item scores are
combined to create a psychological subscale score
which may range from 0 to 33. Physical or somatic
symptoms such as headaches and muscle and joint
pain are measured by items 12–18; the range for the
somatic subscale is 0–21. Vasomotor symptoms (hot
flushes, sweating at night) are assessed by items 19
and 20 and comprise the vasomotor subscale, the
range for this subscale is 0 to 6. Item 21 is a single-
item probe for loss of interest in sex. The total score
may range from 0 to 63.
(c) Center for Epidemiologic Studies Depression Scale
[CES-D; 19]. The CES-D is a self-report questionnaire
that measures a total of 20 cognitive, affective,
behavioral, and somatic symptoms of clinical depres-
sion and can range from 0 to 60, with higher scores
indicating greater distress. The total score is comprised
of interpersonal, positive, and negative affect subscale
scores. The mean score for patients with a diagnosis of
clinical depression is 39, although a score of 16 or
above is considered to be clinically significant for
distress related to depressive symptoms [20].
Statistical analysis
A 3 × 2 group (Pre–Pre, Pre/Peri–Peri, and Post–Post) by
time (baseline and the recovery week of cycle 4) linear
mixed model was performed using R, version 2.10.0 (www.
rproject.org) on seven dependent objective sleep quality
variables collected with actigraphy: TST, % sleep, WASO,
NWAK, mean duration of awakenings, number of sleep
bouts, and mean duration of sleep bouts at night. Nighttime
awakenings (WASO and NWAK) were defined as a period
of wakefulness between two periods of sleep (including
sleep onset); sleep bouts were defined as a period of sleep
between two periods of wakefulness (including sleep
offset). Together, these measurements have been used as
an index of sleep consolidation [12]. The largest group,
Post–Post, was used as the reference group for all linear
mixed-model analyses.
Group differences in demographic, medical, and back-
ground characteristics were assessed with 3 × 2 linear
mixed model for continuous variables and Fisher’s exact
test for categorical variables.
To probe for statistically significant group differences on
the subscale scores and total or global score of the Greene
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Climacteric Scale, the CES-D, and the PSQI, 3 × 2 linear
mixed-model analyses were conducted. The CES-D total
score was included as a covariate in the linear mixed-model
analyses of the actigraphy and PSQI variables to control for
a possible confounding effect of mood on the subjective
and objective sleep variables.
Results
Demographics
Complete data from 69 women were included in the
analyses (see Table 1). The groups were significantly
different in mean age with the Pre–Pre group being the
youngest and the Post–Post group the oldest (P<0.001).
All three groups were similar in BMI, marital status,
income, education, occupation, race, and ethnicity
(P>0.05). Cancer stage was also similar across groups
(P>0.05, Fisher’s exact test). As measured by BMI, a
majority (65.4%) of women in this sample were either
overweight (32.1%; BMI=25–29.9) or obese (33.3%;
BMI=30 or above).
Sleep
The mean actigraphic sleep variables for each group are
shown in Table 2. There was a significant group-by-time
interaction for TST, WASO, % sleep, duration of wake and
sleep bouts, and NWAK. indicating that changes in these
Group Pre–Pre, N=12 Pre/Peri–Peri, N=21 Post–Posta, N=36
Mean age, years (SD) 41.6 (1.3) 45.6 (1.5) 57.9 (1.3)b
Age range years 34–49 34–61 43–79
Mean body mass index (SD) 30.2 (2.6) 26.9 (1.3) 29.9 (1.1)
Ethnicity, N (%)
Caucasian 7 (58.3) 16 (76.2) 28 (77.8)
African American 2 (16.7) 0 (0.0) 2 (5.6)
Hispanic 0 (0.0) 1 (4.8) 2 (5.6)
Asian 1 (8.3) 2 (9.5) 2 (5.6)
Native American 1 (8.3) 1 (4.8) 0 (0.0)
Other 1 (8.3) 0 (0.0) 2 (5.6)
Unknown 0 (0.0) 1 (4.8) 0 (0.0)
Income, N (%)
< $30,000 0 (0.0) 3 (14.3) 8 (22.3)
≥ $30,000 11 (91.7) 16 (76.2) 24 (66.7)
Refused to answer 1 (8.3) 2 (9.5) 4 (11.1)
Education, N (%)
Some high school or less 1 (8.3) 1 (4.8) 0 (0.0)
Completed high school 1 (8.3) 5 (23.8) 10 (27.8)
Some college 4 (33.3) 4 (14.3) 11 (30.6)
Completed college 6 (50.0) 12 (57.1) 15 (41.7)
Marital status, N (%)
Never married 3 (25.0) 2 (9.5) 4 (11.1)
Divorced 1 (8.3) 0 (0.0) 11 (30.6)
Separated 1 (8.3) 1 (4.8) 0 (0.0)
Widowed 0 (0.0) 0 (0.0) 1 (2.8)
Married 7 (58.3) 18 (85.7) 20 (55.6)
Cancer stage, N (%)
I 3 (25.0) 5 (23.8) 11 (30.6)
II 6 (50.0) 12 (57.1) 13 (36.1)
III 2 (16.7) 3 (14.3) 5 (13.9)
III-A 0 (0.0) 1 (4.8) 4 (11.1)
Unknown 1 (8.3) 0 (0.0) 0 (0.0)
Table 1 Demographics by
menopausal status
a Post-menopausal group used as
reference for between-groups
comparisons
b P<0.05
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sleep variables at the end of chemotherapy compared to
baseline were significantly different between women in the
Pre–Pre menopausal group compared to the Post–Post
group (reference group), with the Pre–Pre group exhibiting
a decrease in TST [t(43)=2.29, P=0.03, mean group
difference in change scores=−1.18 h], increase in WASO
[t(43)=2.67, P=0.01, mean group difference in change
scores=1.14 h], decrease in sleep percentage [t(43)=2.15,
P=0.02, mean group difference in change scores=−14%],
shorter duration of sleep bouts [t(43)=1.99, P=0.04, mean
group difference in change scores=−20.32 min], and more
awakenings [t(43)=2.04, P=0.04, mean group difference in
change scores=7.91 discrete awakenings]. There were no
significant differences in these sleep variables for either the
Pre/Peri–Peri or Post–Post groups from baseline to end of
treatment. Group-by-time interactions for number of
sleep bouts and duration of nighttime awakenings were
not significant at the 5% level. However, there was a
main effect of group for both the Pre–Pre and Pre/Peri–
Peri groups for duration of nighttime awakenings,
indicating that both groups had shorter duration of
awakenings than the Post–Post group before and after
chemotherapy [Pre–Pre: t(66)=2.21, P=0.03, mean group
difference=−1.89 min; Pre/Peri–Peri: t(66)=2.39, P=0.02,
mean group difference=−1.69 min].
There were no significant associations between these
objective sleep variables and age, race, ethnicity, BMI,
income, education, occupation, marital status, neo-adjuvant
therapy status, or stage of cancer.
The mean PSQI variables for each group are shown in
Table 3. With regard to self-reported sleep quality, there
was no significant group, time, or group-by-time interaction
effect.
Climacteric status and symptomatology
The mean Green Climacteric Scale variables for each
group are shown in Table 4 and are comprised of the total
score and six subscales: anxiety, depression, psychological
(sum of anxiety and depression), somatic, vasomotor, and
sex. There was no significant main effect of time for either
the anxiety or psychological subscale for any group;
however, there was a significant main effect of time for
the depression subscale, indicating that depressive symp-
toms of menopause increased from baseline to end of
treatment [t(60)=2.43, P=0.02, mean change in score=
1.2]. There was also a significant group-by-time interac-
tion for the vasomotor subscale showing that women
within the Pre/Peri–Peri group reported increased vaso-
motor symptoms at the end of treatment as compared to
the Post–Post group [t(60)=3.03, P=0.004, mean change
in score=1.7]. Furthermore, there was a significant group
effect for the sex subscale showing that women within the
Pre/Peri–Peri group had worse scores on the sex subscale
than women in the Post–Post group both before and after
chemotherapy [t(65)=−2.45, P=0.02, mean difference
between groups=−0.74]. There was no significant group,
time, or group-by-time interaction effect on any of the
remaining subscales or the total score.
Depressive symptoms
The mean CES-D variables for each group are shown in
Table 5 and are comprised of the total score and four
subscale scores: positive and negative affect, somatic, and
interpersonal. Consistent with the Green Climacteric Scale
depression subscale, there was a main effect of time for the
Table 2 Mean (SD) nighttime sleep as measured by actigraphy by menopausal status at baseline and end of treatment
Group Pre–Pre, N=12 Pre/Peri–Peri, N=21 Post–Posta, N=36
Sleep variables Baseline End of
treatment
Baseline End of
treatment
Baseline End of
treatment
Total nighttime sleep time (TST; hours) 6.24 (0.40) 5.60 (0.46)b 6.74 (0.27) 6.87 (0.37) 6.20 (0.23) 6.82 (0.27)
Wake after sleep onset (WASO; hours) 1.79 (0.31) 2.67 (0.30)b 2.07 (0.20) 2.17 (0.20) 2.31 (0.26) 2.10 (0.25)
Sleep percentage, % 77.7 (3.7) 67.3 (3.6)b 76.3 (2.3) 75.5 (2.4) 73.7 (2.7) 77.2 (2.3)
Duration of sleep bouts (minutes) 32.30 (10.27) 18.79 (7.63)b 27.97 (6.61) 27.20 (10.21) 31.25 (4.94) 37.04 (6.94)
Number of sleep bouts 21.26 (3.18) 29.25 (3.23) 25.94 (3.28) 24.67 (2.46) 19.86 (1.66) 20.37 (2.39)
Duration of awakenings (minutes) 5.13 (0.44)c 5.96 (0.60)c 5.34 (0.39)c 5.64 (0.54)c 7.00 (0.53) 6.58 (0.59)
Number of awakenings 21.26 (3.18) 29.25 (3.23)b 26.63 (3.30) 25.21 (2.55) 20.48 (1.70) 20.96 (2.43)
CES-D total score used as covariate in the analyses of all variables
a Post-menopausal group used as reference for between group comparisons
b P<0.05 for group-by-time interaction effect
c P<0.05 for group main effect
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CES-D total score, indicating that overall depressive
symptoms increased from baseline to the end of treatment
for all three groups [F(1,50)=6.02, P=0.02]. There was no
significant effect for either the interpersonal or negative
affect subscales, suggesting no increase or decrease in these
subtypes of depressive symptoms from baseline to the end
of treatment for all three groups. The Post–Post group
evidenced a significant increase in positive affect symptoms
of depression from baseline to the end of treatment
[positive affect: t(35)=3.17, P=0.004].
Depressive symptoms and sleep
CES-D total scores were not significantly related to the
baseline actigraphy or PSQI sleep variables (data not
shown). However, CES-D total scores at the end of
Table 3 Mean (SD) PSQI results by menopausal status at baseline and end of treatment
Group Pre–Pre, N=12 Pre/Peri–Peri, N=21 Post–Posta, N=36
Baseline End of treatment Baseline End of treatment Baseline End of treatment
Global scores 8.50 (3.87) 8.43 (3.74) 6.29 (3.54) 6.83 (4.29) 6.91 (3.43) 7.09 (3.86)
Component scores
Sleep quality 1.50 (0.52) 1.36 (0.93) 1.09 (0.81) 1.20 (0.77) 1.19 (0.78) 1.00 (0.75)
Sleep onset latency 1.00 (0.74) 0.93 (1.00) 0.91 (1.02) 1.05 (0.97) 0.89 (1.01) 0.83 (0.86)
Sleep duration 0.92 (0.51) 1.14 (0.95) 0.62 (0.74) 0.60 (0.68) 0.86 (0.79) 0.69 (0.83)
Habitual sleep 1.33 (1.30) 1.71 (1.33) 0.90 (1.26) 0.79 (1.13) 0.95 (1.22) 0.91 (1.25)
efficiency
Sleep disturbance 1.58 (0.67) 1.29 (0.61) 1.45 (0.60) 1.55 (0.60) 1.65 (0.72) 1.46 (0.65)
Use of sleep 1.17 (1.47) 1.00 (1.18) 0.77 (1.23) 0.75 (1.16) 0.89 (1.28) 1.14 (1.36)
medications
Daytime dysfunction 1.00 (0.85) 1.00 (0.78) 0.77 (0.69) 1.00 (0.86) 0.62 (0.49) 1.14 (0.71)
CES-D total score used as covariate in the analyses of all variables
a Post-menopausal group used as reference for between-groups comparisons no significant comparisons at P<0.05
Table 4 Mean (SD) Greene Climacteric Scale results by menopausal status at baseline and end of treatment
Group Pre–Pre, N=12 Pre/Peri–Peri, N=21 Post–Posta, N=36
Baseline End of treatment Baseline End of treatment Baseline End of treatment
Total score 10.31 (1.98) 12.92 (2.55) 9.17 (1.42) 14.27 (2.09) 10.90 (1.26) 12.78 (1.77)
Subscales
Anxiety 3.54 (0.67) 2.83 (0.63) 3.00 (0.60) 3.6 (0.74) 3.00 (0.35) 3.15 (0.43)
Depression 2.85 (0.65) 4.35 (0.89)b 2.77 (0.48) 4.25 (0.62)b 2.87 (0.39) 4.07 (0.52)b
Psychological 6.39 (1.16) 6.67 (1.31) 5.48 (0.91) 7.48 (1.27) 5.84 (0.71) 7.26 (0.94)
Somatic 2.39 (0.58) 3.17 (0.97) 2.73 (0.57) 2.95 (0.6) 2.38 (0.42) 2.48 (0.55)
Vasomotor 0.62 (0.33) 1.93 (0.58) 0.83 (0.21) 2.7 (0.45)c 1.53 (0.27) 1.73 (0.33)
Sex 0.92 (0.31) 1.25 (0.41) 0.58 (0.15)d 1.06 (0.23)d 1.23 (0.19) 1.35 (0.24)
a Post-menopausal group used as reference for between-groups comparisons
b P<0.05 for time main effect
c P<0.05 for group-by-time interaction effect
d P<0.05 for group main effect
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treatment were related to shorter sleep bouts at the end of
treatment (r=−0.32, P=0.035).
Discussion
This study found that menopausal status before and after
four cycles of chemotherapy was associated with poor sleep
as measured by wrist actigraphy. Women who were pre-
menopausal both before and after chemotherapy had worse
sleep after chemotherapy than before the start of treatment,
spending more time awake during the night and evidencing
more sleep fragmentation at the end of treatment.
Pre-menopausal women also had worse sleep after chemo-
therapy than women who were either pre-menopausal prior
to chemotherapy but evidenced irregular menses after
chemotherapy (i.e., peri-menopausal) or were post-
menopausal. In terms of sleep fragmentation, pre- and
peri-menopausal women had better sleep (i.e., shorter wake
bouts or periods of awakening after sleep onset) than post-
menopausal women both before and after chemotherapy.
Furthermore, the post-menopausal women evidenced no
change in their sleep from pre- to post-chemotherapy.
Attempts were made to further characterize the mecha-
nism behind these group differences in objective sleep.
Firstly, the experience of somatic climacteric symptoms
was consistent with prior research into the effects of
chemotherapy; although the post-menopausal initially
reported the most vasomotor symptoms before chemother-
apy, after chemotherapy the peri-menopausal group expe-
rienced the greatest increase and the most vasomotor
symptoms as compared to the post-menopausal group.
Secondly, the experience of depressive symptoms was
consistent with prior research into the effects of chemo-
therapy. Self-reported menopausal-related mood symptoms
(i.e., depression and anxiety) worsened for all groups after
chemotherapy, although this finding appears to be driven by
an increase in menopausal-related symptoms of depression.
Although no group met the CES-D criteria for clinical
depression, there was a trend for all three groups to have
increased overall depressive symptoms at the end of
treatment. Therefore, despite a well-established association
between depression and sleep disturbance, self-reports of
depressive symptoms failed to account for the sleep
disturbances found in the pre-menopausal women. Further-
more, overall depressive symptoms did not differ between
groups and, with the exception of shortened sleep bouts
after chemotherapy, were not associated with objectively
measured sleep.
Thirdly, although the objective measures of sleep
showed deterioration from before to after chemotherapy in
the pre-menopausal group, self-reported sleep quality did
not change for any of the three groups. This is contrary to
the consistent finding in cancer that subjective measures of
sleep quality and daytime dysfunction do get worse from
before to after chemotherapy [21]. In the current study,
women in all three groups had poor sleep quality as defined
by a global score greater than 5 on the PSQI both before
and after chemotherapy (see Table 3). In a psychometric
study of the PSQI in cancer, Carpenter and Andrykowski
suggested that it may be more appropriate to use a cutoff of
8 or higher to describe poor sleep quality in this population
[22]. Applying this criterion to the current study, only the
pre-menopausal group reported poor sleep quality; this
report was consistent both before and after chemotherapy.
These findings may suggest a misappraisal of the experi-
ence of sleep in the pre-menopausal group before chemo-
therapy which may have contributed to the worsening of
Table 5 Mean (SD) CES-D results by menopausal status at baseline and end of treatment
Group Pre–Pre, N=12 Pre/Peri–Peri, N=21 Post–Posta, N=36
Baseline End of treatment Baseline End of treatment Baseline End of treatment
Global score 9.49 (4.43) 12.67 (9.53)b 12.65 (10.86) 17.88 (14.34)b 11.30 (8.83) 14.65 (11.15)b
Component scores
Positive affect 1.91 (1.97) 2.89 (2.48) 2.40 (3.12) 4.44 (4.53) 2.21 (2.29) 3.77 (3.53)
c
Negative affect 1.77 (1.75) 2.11 (2.20) 3.55 (3.83) 4.25 (3.92) 2.94 (3.03) 3.04 (2.78)
Somatic 4.05 (2.78) 5.56 (3.71) 5.20 (4.85) 6.56 (4.98) 4.33 (3.67) 5.90 (4.50)
c
Interpersonal 0.09 (0.30) 0.00 (0.00) 0.00 (0.00) 0.13 (0.34) 0.12 (0.42) 0.23 (0.67)
a Post-menopausal group used as reference for between-groups comparisons
b P<0.05 for time main effect
c P<0.05 for group-by-time interaction effect
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sleep after chemotherapy; however, the current study does
not provide support for this relationship. Ancoli-Israel, Liu,
Marler, Parker, Jones, et al. [23] suggested that objective
and subjective sleep measures are often unrelated because
reports of sleep time may be overestimated and the time to
fall asleep underestimated. Moreover, in the current study,
as in previously reported studies, the time frame for the
objective and subjective measures was different, as the
PSQI measures sleep over the previous 7 days as compared
to 3 days of actigraphic recording.
Older age, female gender, and Caucasian race all have
been associated with increased reports of sleep problems
[24, 25]. Participants in this study were predominantly
Caucasian (61%), but there were no significant differences
in race or ethnicity. Not surprisingly, our groups signifi-
cantly differed in age, with the post-menopausal women
being oldest and the pre-menopausal women being youn-
gest. Increasing age and post-menopausal status had been
found to predict poor sleep in previous studies, but a similar
relationship was not found in this study. However, our
study was not designed to characterize aging and sleep per
se; as such, our groups have a wide age range and at the
outset of the study all of our participants were recently
diagnosed with a major illness. It is possible that the poor
sleep found in our all our groups was related to the cancer
and the chemotherapy and not to aging.
Cancer stage has been considered a predominant
precipitating factor in sleep disturbance [26] and was as
such considered as a contributing factor. However, there
was no significant difference in the number of women with
each stage of cancer between the three groups, although the
pre-menopausal group demonstrated a higher but non-
significant incidence of stage III. Stage II was the most
predominant cancer stage in all three groups, with the post-
menopausal group demonstrating a higher but non-
significant incidence of stage I cancer. Furthermore, cancer
stage was not associated with any objective sleep variable.
Additionally, our sample was comprised predominantly by
women with adjuvant chemotherapy status and such status
was not associated with any objective sleep variable;
moreover, a larger study that included our sample had
already found no association between neoadjuvant or
adjuvant chemotherapy status and sleep [23].
The limitations of this study included a lack of non-cancer
comparison group, a small pre-menopausal group, uneven
group sizes (but likely representative of the frequency of
menopausal status in women diagnosed with breast cancer
and treated with four cycles of chemotherapy), no follow-up
after the end of cycle 4 of chemotherapy, and no measure of
pain, a possible contributor to disturbed sleep [11]. The
objective measure of sleep, rest–activity actigraphy, was
time-locked to the participants’ chemotherapy schedules and
may have failed to capture weekday/weekend variation.
Previous studies of population-based menopause have found
an association between early peri-menopause and sleep-
disordered breathing [27] which may disrupt sleep, but this
information is not available in this sample.
Another possible limitation of this study was the lack of
an objective measure of menopausal status, such as follicle-
stimulating hormone level. However, in studies of natural
menopause, there is growing evidence that follicle-
stimulating hormone may be an unreliable diagnostic
measure and the onset of irregular menses may be the best
stand-alone indicator of peri-menopause [28–30]. A similar
inconsistency exists in studies of chemotherapy-related
amenorrhea; menopausal status has been determined from
a variety of measures, including age, follicle-stimulating
hormone level, and the occurrence of menses over periods
ranging from 12 months pre-treatment to 5 years post-
treatment [6]. The shorter duration (3 months) of this study
may have misclassified some women as pre-menopausal
that, in a longer study, may have been classified as peri-
menopausal and vice versa.
Our data demonstrate an increase in climacteric symp-
toms by the end of treatment for the pre-menopausal group
that, while not statistically significant, may indicate the
beginning of peri-menopause for women in this group.
However, there is a lack of scientific support for clinical
cut-points using the Greene Climacteric Scale with respect
to menopausal status in either healthy women or women
undergoing chemotherapy.
In conclusion, the findings of this study showed that
women who are pre-menopausal before and after chemo-
therapy have worse sleep than other women. These results
may suggest that the association between peri-menopause
and disturbed sleep is weakened in women being treated
with chemotherapy. No one factor or combination of factors
explained the differences in sleep quality found between
our groups, i.e., neither age, anxiety, cancer stage, depres-
sion, race, ethnicity, marital status nor subjective self-report
of sleep quality was found to contribute to the poorer sleep
found in the pre-menopausal group. These results are
preliminary and further studies and replications are needed.
In particular, physical or psychological factors such as prior
exposure to menopausal symptoms that were not studied
may have protected the peri- and post-menopausal group
from sleep disruption during chemotherapy or made the
pre-menopausal group more vulnerable to the effects of
chemotherapy. Nevertheless, in a clinical environment,
these results suggest that women who do not experience
chemotherapy-related amenorrhea within the first four
cycles may experience more sleep disruption during
chemotherapy treatment. These women may greatly benefit
from early non-pharmacologic interventions such as nutri-
tion counseling, sleep hygiene training, or cognitive
behavioral therapy for insomnia [31–34].
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